These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34645185)

  • 1. [Clinical study of circulating tumor cells in monitoring the efficacy of neoadjuvant immunotherapy for non-small cell lung cancer].
    Li YJ; Chen H; Liao JF; Yuan JL; Chen T; Zhu J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Feb; 55(2):233-238. PubMed ID: 34645185
    [No Abstract]   [Full Text] [Related]  

  • 2. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
    Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
    Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.
    Zhai W; Zhang C; Duan F; Xie J; Dai S; Lin Y; Yan Q; Rao B; Li L; Zhou Y; Zhao Z; Long H; Wang J
    Front Immunol; 2024; 15():1422717. PubMed ID: 39108262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of neoadjuvant immunotherapy on pulmonary function and perioperative outcomes in patients with resectable non-small cell lung cancer].
    Zhu Y; Li JQ; Chang Q; Qiang HP; Lu JH; Feng H; Shen YC; Qian JL; Chu TQ
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):393-398. PubMed ID: 35144337
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
    Sun W; Liu X; Wang C; Jiang Y; Lin D
    Ann Diagn Pathol; 2024 Apr; 69():152268. PubMed ID: 38301396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].
    Chen LF; Fu GZ; Huang DP; Man Y; Jin Y; Dong QT; Huang YB; Chen YC; Wang HQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):977-983. PubMed ID: 31630497
    [No Abstract]   [Full Text] [Related]  

  • 7. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer.
    Li J; Liao Y; Ran Y; Wang G; Wu W; Qiu Y; Liu J; Wen N; Jing T; Wang H; Zhang S
    BMC Pulm Med; 2020 Oct; 20(1):274. PubMed ID: 33081780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
    Xu Y; Ma D; Qin Y; Li S; Li J; Jiang Y; Wang M; Xu Y; Zhao J; Chen M; Cheng W; Hu K; Liu H
    Thorac Cancer; 2023 Jun; 14(17):1635-1639. PubMed ID: 37094918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
    Zeng A; Yin Y; Xu Z; Abuduwayiti A; Yang F; Shaik MS; Wang C; Chen K; Wang C; Fang X; Dai J
    BMC Cancer; 2024 Mar; 24(1):396. PubMed ID: 38553708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
    Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
    Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative method using circulating tumor cells for prediction of the effects of induction therapy on locally advanced non-small cell lung cancer.
    Tarumi S; Gotoh M; Kasai Y; Matsuura N; Okuda M; Go T; Ishikawa S; Yokomise H
    J Cardiothorac Surg; 2013 Jul; 8():175. PubMed ID: 23856305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
    Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
    Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis.
    Chen Y; Qin J; Wu Y; Lin Q; Wang J; Zhang W; Liang F; Hui Z; Zhao M; Wang J
    Int J Surg; 2023 Sep; 109(9):2794-2807. PubMed ID: 37247009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].
    Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
    Hu J; Zhang L; Xia H; Yan Y; Zhu X; Sun F; Sun L; Li S; Li D; Wang J; Han Y; Zhang J; Bian D; Yu H; Chen Y; Fan P; Ma Q; Jiang G; Wang C; Zhang P
    Genome Med; 2023 Mar; 15(1):14. PubMed ID: 36869384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
    Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
    Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
    Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis.
    Gu L; Wang X; Sun Y; Xu Y; Niu X; Zhao R; Yao Y; Jian H; Han Y; Wei J; Chen Z; Lu S
    Front Immunol; 2022; 13():938269. PubMed ID: 36059450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.